Skip to main content Accessibility help
×
Hostname: page-component-7479d7b7d-fwgfc Total loading time: 0 Render date: 2024-07-12T20:36:44.087Z Has data issue: false hasContentIssue false

109 - Pramipexole

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Mirapex, Mirapex ER, Mirapexin Generic?

• Yes

Class

• Antiparkinson agent

Commonly Prescribed for

(FDA approved in bold)

Parkinson’s disease (PD)

Restless legs syndrome (RLS) (not for Mirapex ER)

• Fibromyalgia

How the Drug Works

• Dopamine agonist, with high affinity for presynaptic and postsynaptic D2, D3, D4 receptors (greater affinity for D3), inhibiting dopamine synthesis and release. The antiparkinson action is likely due to D2 agonism within the caudate-putamen. High affinity for D3 receptors might affect impulse control and dyskinesia. The mechanism of action for RLS is probably related to D2 or D3 receptor agonism

• It expresses neuroprotective effects in disease models (e.g., antioxidant, neurotrophic stimulation, attenuates programmed cell death, etc)

• It also has affinity for α2-adrenergic receptors

How Long Until It Works

• PD: weeks

• RLS: days to weeks

If It Works

• PD: may require dose adjustments over time or augmentation with other agents. Most PD patients will eventually require carbidopa-levodopa to manage their symptoms

• RLS: safe for long-term use with dose adjustments

If It Doesn’t Work

• PD: bradykinesia, gait, and tremor should improve. Non-motor symptoms including autonomic symptoms such as postural hypotension, depression, and bladder dysfunction do not improve. If the patient has significantly impaired functioning, add carbidopa-levodopa with or without pramipexole

• RLS: rule out peripheral neuropathy, iron deficiency, thyroid disease. Change to another drug such as a benzodiazepine. Gabapentin enacarbil (not gabapentin) may also be beneficial. In severe cases consider opioids

Best Augmenting Combos for Partial Response or Treatment-Resistance

• For suboptimal effectiveness add carbidopa-levodopa with or without a catechol-O-methyltransferase (COMT) inhibitor. Monoamine oxidase (MAO)-B inhibitors may also be beneficial

• For severe motor fluctuations and/or dyskinesias with good “on” time, functional neurosurgery is an option

• For RLS, can change to a different dopamine agonist (ropinirole, carbidopa-levodopa) or add clonazepam. Gabapentin enacarbil may be beneficial. In severe cases consider opioix1ds

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 400 - 403
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Pramipexole
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.110
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Pramipexole
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.110
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Pramipexole
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.110
Available formats
×